The International Business Times reports on the drug molnupiravir, which has shown positive results in preliminary studies by significantly reducing infection of the virus in patients after five days of treatment.
William Fischer, MD, associate professor of medicine in the division of pulmonary diseases and critical care medicine, and lead investigator of the study at UNC, said there is “potential” in molnupiravir.
Fischer said in a statement: “The secondary objective findings in this study, of a quicker decrease in infectious virus among individuals with early COVID-19 treated with molnupiravir, are promising and if supported by additional studies, could have important public health implications, particularly as the SARS-CoV-2 virus continues to spread and evolve globally.”